Back to search

Aristotle University Of Thessaloniki (AUTH)

Μελέτη της δράσης της μοξονιδίνης στα επίπεδα του νευροπεπτιδίου Υ σε υπερτασικούς ασθενείς με ή χωρίς παχυσαρκία

Abstract

dc:description

Obesity is a multifactorial disease and its occurrence is associated with genetic and environmental factors. It is also, an important factor of morbidity and mortality and is associated with chronic diseases such as Arterial Hypertension, diabetes, dyslipidaimia and cardiovascular disease, constituting thereby an important public health problem that has modern epidemic characteristics.Obesity coexists with Arterial Hypertension, at a rate of 60-70%, while this coexistence increases the cardiovascular risk. The responsible mechanisms for the Arterial Hypertension in obesity are manifold, but one of the most important that has been shown that is the increased activity of Sympathetic Nervous System (SNS). The main regulator of food intake and energy balance is leptin, which interacts especially with the orexigenic NPY. The levels of leptin in obese patients are increased, while there is resistance to the metabolic actions of leptin. The SNS seems to be involved with the creation of Arterial Hypertension in obesity, through the main expressive of the SNS increased activity, NPY, which increase is parallel with the increase of leptin. In our study NPY was a key design parameter in order to relate the reduction of its levels after treatment with Moxonidine -a centrally acting antihypertensive agent and selective agonist of I1 of imidazoline receptors- with the decreasing of SNS activity and thus, with the reduction of blood pressure, body weight and BMI, and the improvement of glycaemic and lipid profile of patients.In our study, the levels of NPY in combination with the activity of SNS (secretion of catecholamines), were observed in hypertensive patients and they correlated with the body weight, by determining the levels of NPY, urine catecholamines and catecholamines’ metabolites (VMA), before and after treatment with moxonidine.Also, the antihypertensive action of Moxonidine was evaluated, especially according to the reduction of the SNS, with a corresponding effect on NPY, in order to confirm the role of NPY to the pathogenesis and a possible target for the treatment of Arterial Hypertension in obese.The study enrolled 90 patients from the outpatient clinic of the First Propedeutic Pathology Clinic of AHEPA Hospital – Internal medicine Clinic, Hypertension Center (Excellence Center), Obesity Center (Center of Obesity Management – COM) and Lipid outpatient- and patients hospitalized in the First Propedeutic Internal Medicine Clinic. The patients had mild and moderate Arterial Hypertension, according to the guidelines of JNC and ESH / ESC, videlicet first and second grade Arterial Hypertension, that required monotherapy.The patients, after 14 hours fasting, were bled for count of general blood and biochemical parameters (glucose, lipidaimic and renal parameters). Furthermore, in patients determined the levels of plasma NPY, with ELISA method (Enzyme-Linked Immunosorbent Assay) and the levels of urine adrenaline, noradrenaline and VMA in 24 hours measurement.The patients were subdivided according to the BMI in normal weight, overweight and obese, in respective groups by gender. They were treated for 12 weeks with moxonidine, in dose titrated up to 0,6 mg per day, to achieve the objective levels of blood pressure. At the end of this period, determined again the initial measurement of the predetermined markers.After analysis and statistical processing by descriptive (statistical indicators and graphical methods for quantitative description data) and inferential statistical analysis (control two means and analysis of variance), the results of our study are summarized as follows:A reduction was observed in SBP, DBP, heart rate, body weight and BMI, in all patients treated with Moxonidine, regardless of sex and dose. Similarly, there was a decrease of NPY, of urinary catecholamines, and of these urinary metabolite – VMA.Regarding the lipid profile, there was a statistically significant reduction in total cholesterol and in LDL, to all patients, treated with Moxonidine. When the analysis was sex specific, a statistically significant reduction in total and LDL cholesterol values, was seen before and after treatment, in women groups.For the HDL levels there was no statistically significant increase of the mean value after the treatment, but observed an increasing tendency of HDL levels ,before and after treatment, in the total patients and in both sexes.We observed a voltage reduction in triglycerides, in total patients, and in the individual groups, but the difference in their levels after treatment was statistically significant only in the group of obese.Regarding the effect of Moxonidine on glycaemic profile of patients, a clear downward trend was observed in overweight, in obese and in total patients and by gender.A decreasing trend was observed regarding the levels of uric acid, by the administration of Moxonidine, both in total and in separate groups, but this reduction was not able to reach statistical significance. Also, the renal function, as estimated using the biochemical markers of urea and creatinine, was not affected.Finally there was a significant reduction in the level of white blood cells after administration of Moxonidine, in the total patients, in the group of obese, obese men and obese women and there was an increasing tendency in overweigt, overweigt men and overweigt women. These finds also, reflects the reduction in the tone of SNS, by granting Moxonidine.When the groups were compared with each other, there was no statistically significant difference in mean reduction in SBP and DBP. In contrast, there was a difference in mean reduction of BMI and NPY, with the largest mean decrease in the group of obese and overweight compared with the group of normal weight. It was observed a reduction of the mentioned clinical and laboratory indices when the comparison was regard sex, with some individual variations, but with out clinical value.It is concluded, that the administration of Moxonidine, a centrally acting sympatholytic drug, in patients with Arterial Hypertension, obese or not, results in a significant reduction of blood pressure -SBP and DBP- and heart rate and affects favorably on metabolic, glycaemic and lipid profile of these patients. The decrease of NPY, which is the main biochemical exponent of SNS activity, causes a reduction in body weight, BMI and this makes the Moxonidine an antihypertensive agent with potential "pleiotropic" actions.Based on our stydy results, it may be revealed a new possible use of NPY, because this sensitive indicator is easy to measure and also, in daily clinical practice can be a therapeutic goal and simultaneously a prognostic factor of response of hypertensive obese patients in Moxonidine treatment.In particular, the detection of high levels of NPY before initiation of treatment, indicating the increased activity of SNS, as the main pathophysiological mechanism creation of Arterial Hypertension in the patients of the study, compared to other involved mechanisms (hyperinsulinemia, increased fluid retention, increased activity of cellular pumps, such as sodium-hydrogen, hypertrophy-hyperplasia of smooth muscle). Therefore, as a consequence, the inhibition of SNS activity, with a centrally acting drug, such as Moxonidine, which simultaneously has a neutral or favorable effect on metabolic profile of patients and can significantly reduce both blood pressure, and weight gain, that accords with the NPY reduction, obtains a particular indication.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2016

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Karlafti, Eleni
  • Καρλάφτη, Ελένη

Subjects

dc:subject × 12

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/37737

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Karlafti, Eleni; Καρλάφτη, Ελένη. Μελέτη της δράσης της μοξονιδίνης στα επίπεδα του νευροπεπτιδίου Υ σε υπερτασικούς ασθενείς με ή χωρίς παχυσαρκία. Aristotle University Of Thessaloniki (AUTH), 2016. http://hdl.handle.net/10442/hedi/37737